NextImmune has identified a novel class of small molecules that suppress unwanted autoimmune responses and transplant rejection responses while maintaining the immune responses needed to defend against infections and cancers.
NextImmune has raised €148k across 1 funding round from 1 investor, most recently a round in Jun 2022. Based in Basel, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-06-27 | Other |
| €148k |
| Venture Kick |
| View deal → |
